[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cap\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cap":53},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100657742","phase-2-an-open-label-multicenter-parallel-group-randomized-clinical-trial-assessing-non-inferiority-of-inhaled-lexofloxacin-vs-usual-care-for-treatment-of-community-acquired-pneumonia-100657742",false,"NCT07843017","Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia","Local Antibiotic Delivery for Community Acquired Pneumonia","LANDCAP 2","Inclusion Criteria:\n\n1. Hospital admission within 24 hours.\n2. Clinical suspicion of community-acquired pneumonia necessitating antibiotic treatment.\n\n   Defined as one or more of the following:\n   * Chest X-ray, CT or ultrasound findings consistent with bacterial pneumonia\\*\n   * Symptoms consistent with bacterial pneumonia (such as dyspnea, tachypnea, cough or purulent sputum)\n3. C-reactive protein \\>50 mg\u002FL OR central body temperature \\>38.0 °C OR blood leukocytes ≥10.0×109\u002FL (1-3 of these fulfilled).\n4. Age ≥ 18 years.\n5. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Suspected septic shock defined as MAP \\\u003C 65 mmHg on sequential measurements despite adequate volume resuscitation.\n2. Oxygen requirement \\>4L\u002Fmin to maintain acceptable peripheral oxygen saturation\\*.\n3. Significant suspicion of an infection with a focus other than the lungs\n4. Contraindications for fluoroquinolone treatment, including but not limited to:\n\n   * Known allergy to fluoroquinolones or a serious adverse reaction when previously treated with a fluoroquinolone.\n   * Medical history of myasthenia gravis.\n5. Reduced kidney function (eGFR \\\u003C 20 mL\u002Fmin\u002F1.73 m²).\n6. Suspected aspiration pneumonia, pulmonary abscess, or pleural empyema \u002F complicated parapneumonic effusion.\n7. Suspicion of clinically significant cardiac conduction disorders\u002Farrhythmias or prolonged QTc interval (QTc (f) \\> 480ms).\n8. Pregnancy\\*\\*.","ALL","18 Years",{"count":20,"type":21},460,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","This trial aims to determine whether treatment with inhaled levofloxacin (an antibiotic) is equal to systemic antibiotic treatment (usual care) for patients admitted to a hospital with community-acquired pneumonia in regards to treatment-effect and safety parameters.\n\nAdditionally, this study will assess if treatment with inhaled antibiotics leads to fewer antibiotic side-effects and a more preserved gastro-intestinal microbial environment.\n\nThe main question this study aims to answer is:\n\nDoes inhaled levofloxacin 240mg twice daily result in comparable days alive and out of hospital at 14 days compared to standard-of-care (usual care) antibiotic treatment for community-acquired pneumonia in admitted patients?\n\nSecondary questions this study aims to answer are:\n\n1. Does treatment with inhaled levofloxacin reduce proportion of patients with antibiotic side-effects?\n2. Does treatment with inhaled levofloxacin lead to preserved diversity in the gut microbiome?\n3. Is treatment with inhaled levofloxacin comparable with usual care in regards to patient reported outcomes?\n\nThe above list is not the complete list of questions this study aims to answer, but serves as highlights.",[28,29,30,31,32],"Community-acquired Pneumonia","CAP","Community Acquired Pneumonia","Pneumonia","Microbial Composition",[34,35,36,37,38,29,31,39,40],"Inhaled antibiotics","Nebulized antibiotics","Aerosolized antibiotics","Levofloxacin","Flourquinolone","Community-acquired","Community acquired","NOT_YET_RECRUITING","2026-09-25",{"date":44,"type":45},"2026-09-30","ACTUAL",{"date":47,"type":21},"2026-09-28",{"date":49,"type":21},"2029-09-01",{"name":51,"class":52},"Copenhagen Respiratory Research","NETWORK","Cap"]